Article Text

Download PDFPDF

The CD4+/CD14+HLA-DRlo/neg ratio as a prognostic biomarker in cancer patients
  1. Allan B Dietz1,
  2. Michael P Gustafson1,
  3. Yi Lin2,
  4. Betsy LaPlant3,
  5. Courtney J Liwski1,
  6. Mary L Maas1,
  7. Stacy C League4,1,
  8. Philippe R Bauer5,
  9. Roshini S Abraham4,1,
  10. Matthew K Tollefson6,
  11. Eugene D Kwon6 and
  12. Dennis A Gastineau1,2
  1. Aff1 grid.66875.3a000000040459167XLaboratory Medicine and PathologyMayo Clinic Rochester MN USA
  2. Aff2 grid.66875.3a000000040459167XHematologyMayo Clinic Rochester MN USA
  3. Aff3 grid.66875.3a000000040459167XBiomedical StatisticsMayo Clinic Rochester MN USA
  4. Aff4 grid.66875.3a000000040459167XCellular and Molecular ImmunologyMayo Clinic Rochester MN USA
  5. Aff5 grid.66875.3a000000040459167XPulmonary and Critical Care MedicineMayo Clinic Rochester MN USA
  6. Aff6 grid.66875.3a000000040459167XUrologyMayo Clinic Rochester MN USA

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts

The immune status of an individual is made up of the absolute number (cells/μl) and relative ratios of each category of immune cells. To determine the extent of similarity of the immune status between individuals across malignancies, we described the immune status using quantitative whole blood flow cytometry of ten immune markers and generated immune phenotypes from 40 healthy volunteers and 120 patients with glioblastoma, renal cell carcinoma, non-Hodgkin’s lymphoma, ovarian cancer or with a non-malignant condition (acute lung injury). After normalization, we used unsupervised hierarchical clustering and principal component analysis to sort individuals by similarity of immune status into discreet groups of immune profiles. Immune profiles sort not only patients by immune similarity, but they also identify independently regulated immune markers. We noticed an inverse relationship between the number of CD14+HLA-DRlo/neg monocytes and CD4+ T cells. We found that the combination of these markers acted as a potent novel biomarker for assessing the patients’ immune status. Using survival and immunophenotype data from glioblastoma, renal cell carcinoma, non-Hodgkin’s lymphoma patients, we calculated the ratio of the number of CD4+ T cells to the number of CD14+HLA-DRlo/neg monocytes (cells/μl) and subgrouped those with a high or low ratio, with a cut-point ratio of 2.0. The 40 healthy volunteers had a mean CD4+/CD14+HLA-DRlo/neg ratio of 39.8 (median 22.5) with a minimum of 3.9. We analyzed the overall survival of GBM, NHL, and RCC patients with high and low ratio using multivariate analysis to control for age and disease type. The median overall survival for patients with a ratio above 2.0 was 30 months (n=68) compared to 9 months for patients with a low ratio (n=39; p=0.006 by multivariate analysis). Thus, the CD4+/CD14+HLA-DRlo/neg ratio has the potential to be a powerful biomarker for risk stratification and prognosis for a broad array of malignancies.